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Background/Purpose: Aeromonas infections, rarely reported in Western countries, are not uncommon infec-
tious diseases in Taiwan. The clinical manifestations and prognostic factors of Aeromonas spontaneous
bacterial peritonitis (SBP) in patients with liver cirrhosis were investigated.
Methods: We reviewed the medical charts and microbiological records of liver cirrhosis patients with
Aeromonas SBP between January 1990 and December 2005, in a medical center in southern Taiwan.
Results: Thirty-one liver cirrhosis patients developed Aeromonas SBP within a 16-year period. The majority
(26, 84%) had concurrent Aeromonas bacteremia. A. sobria (55%) and A. hydrophila (45%) were the causative
species. The predominant clinical manifestations included fever (84%), abdominal pain (74%), hypotension
on admission (48%), altered mental status (45%), and acute renal failure (42%). Gram-negative bacilli
were found in Gram staining of ascitic fluids in 27% of 26 patients, while aeromonads were isolated from
ascitic fluids in 55% of 31 patients. The yield rate of ascitic fluid cultures decreased greatly, if paracentesis
was performed at > 3 hours after the administration of antimicrobial therapy. All but one patient received
in-vitro-active antimicrobial agents within 48 hours, but the all-cause mortality rate was 56%. Initial high
Pitt’s bacteremia score was independently associated with a fatal outcome in multivariate analysis.
Conclusion: Aeromonas SBP is a fatal disease, and must be included in the differential diagnosis of SBP in
patients with advanced liver cirrhosis in endemic areas. [J Formos Med Assoc 2009;108(4):293–300]
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ORIGINAL ARTICLE
Aeromonas species are oxidase-producing Gram-
negative rods and aquatic microorganisms, and
have been implicated in a variety of human dis-
eases. They have been isolated from chlorinated
and fresh water, and are ubiquitous in fresh
water, fish and shellfish, meats, and fresh vegeta-
bles.1 The reported routes of entry for Aeromonas
species include oral consumption of contaminated
food1 or exposure of wounds to environmental
sources that contain aeromonads.2 The spectrum
of Aeromonas infections in humans has expanded,
and includes acute gastroenteritis, hepatobiliary
tract infections, peritonitis, pneumonia, empyema,
meningitis, endocarditis, and skin and soft tissue
infections.2–5 Among these, peritonitis is an un-
common yet serious Aeromonas infection, which
presents in three distinct clinical settings: spon-
taneous bacterial peritonitis (SBP), peritonitis in
chronic ambulatory peritoneal dialysis, or intes-
tinal perforation.4
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Escherichia coli is the most common organism
that causes SBP, and is responsible for 40–63% of
cases.6–10 In Taiwan, major pathogens are E. coli
and Klebsiella pneumoniae, which altogether account
for 71% of isolates.11 However, it has been recog-
nized that patients with liver cirrhosis are suscep-
tible to invasive Aeromonas infections,2,12,13 and
such a clinical association is especially evident in
southern Taiwan. We have reported that 54% of
104 cases of monomicrobial Aeromonas bacteremia
had liver cirrhosis, and the mortality rate was 39%
among the latter patients.13 Moreover, Aeromonas
species are responsible for 14.2% of Gram-nega-
tive-bacillus bacteremia in liver cirrhosis patients in
Taiwan.14 Clinical cases of Aeromonas SBP have also
been occasionally encountered in Taiwan,12,13,15
Korea,10 Spain,16–18 and northern Europe.19
Few studies have focused on clinical aspects of
Aeromonas SBP in patients with liver cirrhosis. We
investigated the clinical manifestations and prog-
nostic factors of Aeromonas SBP in liver cirrhosis
patients.
Methods
The medical charts and microbiological records
of liver cirrhosis patients with Aeromonas SBP 
in National Cheng Kung University Hospital, a
university-affiliated medical center with approxi-
mately 900 beds in Tainan, Taiwan, were collected
between January 1990 and December 2005. Gram-
negative bacilli isolated from blood or ascitic fluid
were identified as Aeromonas species on the basis
of the following findings: a positive oxidase reac-
tion, no growth on thiosulfate/citrate/sucrose agar,
growth on MacConkey agar, and resistance to
vibriostatic compound O/129 (150 μg). Biochem-
ical profiles of the API system (BioMerieux, Marcy-
I’Etoile, France) were utilized for identification
of aeromonads to the species level. The Kirby–
Bauer disk-diffusion method was used for in vitro
susceptibility testing. Antibiotics tested included
ampicillin/sulbactam, cephalosporins (cephalo-
thin, cefuroxime, ceftriaxone), aminoglycosides
(amikacin, gentamicin), and fluoroquinolones
(norfloxacin, lomefloxacin, levofloxacin, oflo-
xacin). The breakpoint zone for susceptibility or
resistance followed the recommendations of the
Clinical and Laboratory Standards Institute for
Enterobacteriaceae.20
According to the consensus of the International
Ascites Club, diagnosis of SBP is based on an as-
citic fluid polymorphonuclear leukocyte count
≥ 250/mm3 by diagnostic paracentesis, and exclu-
sion of secondary peritonitis.21 The demographic
data, underlying diseases, place of acquisition 
of infection, history of consumption of seafood or
un/undercooked food, wound exposure to soil or
water, initial presentations, laboratory parameters,
microbiological reports, antimicrobial suscepti-
bility, time to perform paracentesis in relation to
initiation of in-vitro-active antimicrobial therapy,
clinical course and outcome of eligible cases were
collected.
The Child–Pugh classification was used to
evaluate the degree of hepatic decompensation
in patients with liver cirrhosis.22 The severity of
acute illness at the onset of Aeromonas infections
was assessed by Pitt’s bacteremia score, calculated
within 1 day after hospital admission, a previ-
ously validated scoring system that was based on
mental status, body temperature, blood pressure,
requirement for mechanical ventilation, and re-
cent cardiac arrest.23 Hypotension was defined as
low systolic blood pressure (< 90 mmHg) or the
need for inotropic agents to maintain blood pres-
sure. Acute renal failure was defined as an incre-
ment of serum creatinine about 0.5 mg/dL from
baseline in patients with baseline level <3.0mg/dL,
or an increment of 1.0 mg/dL in patients with
baseline creatinine level > 3.0 mg/dL. Critical ill-
ness was defined as that described by Pitt with 
a bacteremia score of ≥ 4 points. Time to defer-
vescence was defined as the period between the
initiation of antimicrobial therapy and the first
day of 3 consecutive days with a sustained body
temperature < 37°C. The maximal or minimal
levels of peripheral hemograms, serum biochem-
istry and coagulation profiles between 24 hours
before and within 48 hours after onset of Aero-
monas diseases, were recorded and analyzed. Ascitic
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fluid examination included total leukocyte counts,
differential leukocyte count, bacterial culture, Gram
staining, and total protein levels.
For statistical evaluations, the χ2 test or Fisher’s
exact test for binary data, and the Mann–Whitney
U test for continuous scaled data were applied. A
value of p < 0.05 was considered to be statistically
significant.
Results
During the 16-year study period, 31 patients with
liver cirrhosis fulfilled the diagnostic criteria of
Aeromonas SBP. Their mean age was 55 years (range,
27–82 years), and seven (23%) patients were
aged >65 years. There was a predominance of male
patients (22 cases, 71%). Twenty-six (84%) patients
acquired Aeromonas infections in the community.
According to the grading system for hepatic de-
compensation, 3 (10%) cases had Child–Pugh B
cirrhosis, and 28 (90%) had Child–Pugh C cirrho-
sis. Mean Pugh score was 12.4 ± 1.8 (range, 8–15).
Thirteen (42%) patients had concomitant hepa-
tocellular carcinoma, and six (19%) had diabetes
mellitus. Oral consumption of undercooked food
or seafood, or recreational exposure to contami-
nated soils or water before illness, was not evident
in any patient, according to chart records.
Etiological pathogens
The results of ascitic fluid culture were available
for all patients. Of 30 patients in whom blood
culture was performed, 26 (87%) had concurrent
Aeromonas bacteremia. A. sobria and A. hydrophila
were the causative organisms, accounting for 55%
(17 cases) and 45% (14), respectively. Overall, 54%
and 61% of Aeromonas isolates were susceptible
to cephalothin and cefuroxime, respectively. Cef-
otaxime, gentamicin, amikacin and levofloxacin
were active in vitro against all isolates tested.
Clinical features
Fever (26 cases, 84%) and abdominal pain (23,
74%) were the major manifestations of Aeromonas
SBP among 31 cases. The clinical triad of peritonitis,
i.e. fever, abdominal pain and rebounding ten-
derness, was present in only six (19%) cases. Of
26 cases with fever, the majority (23 cases, 88%)
visited the hospital within 24 hours. Among eight
cases without abdominal pain or tenderness, five
complained of vague abdominal fullness. Of note,
three (10%) cases of Aeromonas SBP denied any
localized abdominal symptom or sign. Hypoten-
sion, acute renal failure and upper gastrointestinal
bleeding were recognized in 15 (48%), 13 (42%)
and 7 (23%) cases, respectively. Diarrhea was an
infrequent symptom, and only noted in two (6%)
cases. None of these patients had associated soft
tissue infection. Mean value of Pitt’s bacteremia
score at admission was 4.0 ± 3.7, and 13 (42%)
cases had a score of ≥ 4 points, which was indi-
cative of critical illness.
Laboratory findings
Nine (28%) of 30 cases had leukopenia (leuko-
cyte count < 4000 cells/mm3), and 7 (23%) had
leukocytosis (leukocyte count >10,000 cells/mm3)
(Table 1). Twenty-five (83%) of 30 cases had
thrombocytopenia (platelet count < 100,000 cells/
mm3). Mild elevation of aspartate and alanine
Aeromonas spontaneous bacterial peritonitis
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Table 1. Laboratory findings of 31 liver cirrhosis patients with
Aeromonas spontaneous bacterial peritonitis
Laboratory data [case number] Mean ± SD (range)
Blood or serum
Leukocytes (cells/mm3) [30] 6947 ± 4852 (1000–22,400)
Platelets (×103 cells/mm3) [30] 64 ± 42 (22–200)
AST (IU/L) [31] 180 ± 282 (35–1616)
ALT (IU/L) [31] 85 ± 87 (20–391)
Total bilirubin (mg/dL) [31] 11 ± 10 (2–51)
Albumin (g/dL) [30] 2.5 ± 0.5 (1.8–3.7)
Prolongation of prothrombin 7.9 ± 6.6 (0.3–34.2)
time (s) [31]
Ascitic fluid
Leukocytes (cells/mm3) [31] 13,653 ± 19,175 (330–75,400)
Neutrophils (cells/mm3) [31] 12,548 ± 17,854 (271–67,860)
% of neutrophils [31] 90 ± 8 (58–98)
Total protein (mg/dL) [25] 1245 ± 866 (107–3420)
Glucose (mg/dL) [17] 85 ± 82 (17–271)
SD = standard deviation; AST = aspartate aminotransferase; ALT = alanine amino-
transferase.
aminotransferases (AST and ALT) was noticed.
Among 31 patients, AST and ALT levels were
< 400 IU/dL, except one case with AST level of
1616 IU/dL. Elevated total bilirubin level (> 3 mg/
dL) were seen in 26 (84%) of 31 cases, while 
decreased albumin level (< 3 mg/dL) was seen in
24 (80%) of 30 cases. There was a prolongation
of prothrombin time of 8 seconds on average.
Abdominal paracentesis was performed in all
cases, and the results of cell count, biochemistry
and microbiological surveys of ascitic fluid are
listed in Table 1. Elevated leukocyte counts (mean,
12,548 cells/mm3; range, 271–67,860 cells/mm3)
and protein concentrations (mean, 1245 mg/dL;
range, 107–3420 mg/dL) were found.
Microbiological studies
Gram staining of ascitic fluid disclosed Gram-
negative bacilli in 7 (27%) of 26 cases, while
aeromonads could be isolated from 17 (55%) of
31 cases. The microbiological data from peritoneal
fluid were further categorized into a pretreatment
group (peritoneal fluid obtained prior to antimi-
crobial therapy) and posttreatment group (fluid
obtained after initiation of effective antimicrobial
therapy). In both groups, the yield rate of Gram
staining of ascites was similar (5/17, 29% in the
pretreatment group vs. 2/9, 22% in the posttreat-
ment group; p = 0.69). However, the isolation rate
of ascitic fluid culture was higher in the pretreat-
ment group (14/21, 67% vs. 3/10, 30% in the post-
treatment group; p = 0.055). Of note, bacterial
cultures of ascitic fluid obtained within 3 hours
after antimicrobial therapy in three patients were
all positive, while those obtained more than 3
hours after antimicrobial therapy in seven patients
were all negative (p = 0.002). In one patient in
whom ascitic fluid was obtained 13 hours after
in-vitro-active antimicrobial therapy, Gram staining
remained positive, while the culture was sterile.
Treatment and clinical outcome
All but one case of Aeromonas SBP received at least
a parenteral antibiotic within 48 hours of a diag-
nosis of peritonitis. The exception was a case of
Child C liver cirrhosis with Aeromonas SBP, which
spontaneously resolved without antimicrobial
therapy. In the initial 3 days of empirical therapy,
25 (81%) cases received an in-vitro-active drug (22
cases with ceftriaxone or cefotaxime, and one each
with cefuroxime, fluoroquinolone or aminogly-
coside); four (13%) received combination therapy
with an in-vitro-active cephalosporin and amino-
glycoside; and one was treated with ineffective
cefazolin. Overall, 24 (77%) cases were treated by
a third-generation cephalosporin (ceftriaxone or
cefotaxime) as initial empirical treatment. Compar-
ing cases treated with one or two effective drugs,
there was no significant difference in all-cause
mortality rate at 3 days (50% vs. 59%; p = 0.62) or
2 weeks (40% vs. 50%; p = 0.73). All-cause mor-
tality rate at 2 weeks among cases receiving em-
pirical cefotaxime or ceftriaxone therapy was not
significantly different from that of cases receiving
other drugs (37% vs. 57%; p = 0.35). Overall, the
all-cause mortality rate at 3 days and 2 weeks and
inhospital mortality rate were 38% (12 cases),
41% (13 cases), and 56% (18 cases), respectively.
Mean duration of hospitalization before death
in 18 fatal cases was 7.6 ± 8.4 days (range, 1–30
days). Of 13 surviving cases, mean time to defer-
vescence was 2.1 ± 1.6 days (range, 0–5 days),
and mean hospital stay was 14.1±11.0 days (range,
3–43 days).
By univariate analysis, significant risk factors
for all-cause fatality at 2 weeks included an initial
high Pitt bacteremic score, high Pugh score, altered
mental status, hypotension, upper gastrointestinal
bleeding, acute renal failure, elevated levels of
serum aminotransferases, and prolongation of
prothrombin time (Table 2). Bacteremic cases had
a higher mortality rate than non-bacteremic cases,
although the difference was not statistically signi-
ficant (13/26, 50% vs. 0/4, 0%; p = 0.06). Presence
of abdominal pain or rebound tenderness, or 
absence of fever were not associated with poor
prognosis. Besides, none of age, sex, place of ac-
quisition of infection, underlying hepatocellular
carcinoma or diabetes mellitus, Aeromonas species,
blood leukocyte or platelet counts, serum albumin
levels, ascitic leukocyte count, or bacterial growth
in ascitic fluid, was significantly associated with
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a grave prognosis. By multivariate analysis, only a
Pitt bacteremic score of ≥4 points was significantly
associated with fatality at 2 weeks.
Discussion
Unlike in Western countries where aeromonads are
reported infrequently as the causative organisms,
SBP caused by aeromonads is occasionally 
encountered in Taiwan12,13 and Korea.10 During a
16-year period, 31 cases with monomicrobial
Aeromonas SBP were diagnosed in our hospital.
There are at least two explanations for the sig-
nificant number of cases of Aeromonas SBP in
Taiwan. First, aeromonads are ubiquitous in
Taiwan, and they are found in 88% of seafood
from the retail markets and supermarkets in
Aeromonas spontaneous bacterial peritonitis
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Table 2. Risk factors for all-cause 14-day mortality among 31 patients with Aeromonas spontaneous
bacterial peritonitis by univariate analysis*
Fatal group (n = 13) Survival group (n = 18) p
Host factors
Male gender 10 (77) 12 (67) 0.696
Child–Pugh score 13.5 ± 1.3 11.6 ± 1.6 0.002
Hepatocellular carcinoma 8 (62) 10 (56) 1.000
Diabetic mellitus 3 (23) 3 (17) 0.676
Clinical presentations
Nosocomial infections 1 (8) 4 (22) 0.368
Pitt bacteremia score 7.5 ± 2.9 1.4 ± 1.5 < 0.001
Pitt bacteremia score ≥ 4† 12 (92) 1 (6) < 0.001
Fever 12 (92) 14 (78) 0.368
Abdominal pain 9 (69) 14 (78) 0.689
Rebounding tenderness 3 (23) 5 (28) 1.000
Hypotension at presentation 12 (92) 3 (17) < 0.001
Altered mental status 11 (85) 3 (17) < 0.001
Gastrointestinal bleeding 6 (46) 1 (6) 0.012
Acute renal failure 9 (69) 4 (22) 0.013
Laboratory findings
Total bilirubin (μmol/L) 14.0 ± 13.6 8.6 ± 6.5 0.157
AST (IU/L) 301 ± 407 91 ± 58 0.039
ALT (IU/L) 107 ± 84 69 ± 87 0.238
Prolongation of prothrombin time (s) 11.0 ± 8.3 5.6 ± 3.8 0.020
Peripheral leukocyte count (cells/mm3) 6561 ± 5701 7241 ± 4252 0.711
Peripheral platelet count (cells/mm3) 61,385 ± 31,266 66,471 ± 48,841 0.746
Serum albumin (mg/dL) 2.6 ± 0.6 2.5 ± 0.4 0.949
Ascitic leukocyte count (cells/mm3) 18,609 ± 21,540 10,073 ± 16,998 0.227
Positive blood culture 13 (100) 13 (72) 0.058
Positive ascitic culture 8 (62) 9 (50) 0.717
Treatment
Time interval between admission and initiation 12.5 ± 12.8 7.9 ± 18.3 0.496
of effective antimicrobials (hr)‡
Initial treatment with cefotaxime or ceftriaxone 9 (69) 15 (83) 0.413
Initial therapy with 2 effective antimicrobial agents 2 (15) 2 (11) 1.000
*Data presented as n (%) or mean ± standard deviation; †only Pitt bacteremia score ≥ 4 achieved significant difference between the
two groups by multivariate analysis; ‡only 25 patients with community-acquired Aeromonas spontaneous bacterial peritonitis were 
analyzed, of whom 13 survived.
Taipei, a city located in northern Taiwan.24
Although a history of oral consumption of sea-
food or undercooked food could not be traced in
our patients, it is likely that aeromonads can be
encountered in the environment, not only in
seafood but also in drinking water. Second, the
prevalence of individuals with chronic liver dis-
eases and liver cirrhosis, who are susceptible to
invasive Aeromonas infections, is high in Taiwan,
as 15–20% of the general population here has
chronic hepatitis B infection,25 and 2.9–5.4%
has hepatitis C.26 Therefore, in Taiwan, Aeromonas
infections must be included in the differential
diagnosis of SBP.
In the present study, the Aeromonas species
that caused SBP were mainly A. hydrophila and 
A. sobria, while A. caviae was not encountered, in 
accordance with the study of Munoz et al,4 in
which A. hydrophila and A. sobria accounted for
82% and 18% of 22 cases of Aeromonas SBP, re-
spectively, while A. caviae SBP was not detected.
Similarly, among 22 cases of Aeromonas peritonitis
reported by Huang et al,15 95% of cases were
caused by A. hydrophila and 5% by A. sobria. This
was probably associated with the relative patho-
genicity of individual Aeromonas species. It has
been recognized that A. hydrophila and A. sobria
are inherently more pathogenic than A. caviae
in mice.27 Moreover, clinical A. hydrophila and A.
sobria isolates more often produced toxin in broth
or human pooled ileostomy fluid, and adhere
more readily to Vero or A-549 cells than does 
A. caviae.28 In our hospital from 1998 to 2005,
86.8% (118) of 136 episodes of A. hydrophila bac-
teremia and 81.9% (68) of 83 episodes of A. sobria
bacteremia were monomicrobial bacteremia, and
in contrast, only 56.2% (41) of 73 episodes of 
A. caviae bacteremia were monomicrobial bac-
teremia (p<0.001) (unpublished data). The above
microbiological and clinical findings suggest the
relatively low virulence of A. caviae.
In general, clinical manifestations and disease
severity of SBP vary greatly, and patients can be
symptomatic and critically ill, slightly sympto-
matic, or even asymptomatic.8,29,30 In our study,
Aeromonas SBP mainly developed in subjects with
decompensated liver cirrhosis, as demonstrated
by the fact that 90% of cases were classified as
Child–Pugh C. Not surprisingly, fever and ab-
dominal pain were the prominent presentations.
Moreover, such an infection was an acute and 
severe illness, often presenting with fever and chills
initially, and urged the affected individuals to 
attend the hospital within 24 hours after the onset
of relevant symptoms. Nearly half of the cases
experienced shock and altered mental status at
admission, and were considered as having critical
conditions, as suggested by high Pitt bacteremic
scores. Although cases of SBP usually experienced
abdominal discomfort, 25% and 75% of our pa-
tients had no abdominal pain or rebounding
tenderness, respectively. Furthermore, the clinical
triad of peritonitis, i.e. fever, abdominal pain and
rebounding tenderness, was found only in 19%
of cases, which was less than the 40% mentioned
in a study in Singapore.30 As a result, not all pa-
tients with SBP fulfilled the clinical triad, which
indicates the difficulty and complexity of clinical
diagnosis of SBP. Moreover, Aeromonas SBP was
indistinguishable from that caused by other en-
teric organisms. Thus, the accuracy of microbio-
logical identification by a clinical microbiological
laboratory is indispensable for the diagnosis of
Aeromonas SBP.
As expected in the cases of SBP caused by other
Gram-negative bacilli, increasing polymorpho-
nuclear leukocytes and protein concentrations 
in ascitic fluid were present in Aeromonas SBP.
However, the yield rate of ascitic cultures was 
related to the timing of antimicrobial therapy. 
In ascitic fluid collected before administration of
therapy, the yield rate of bacterial cultures was
higher than that obtained after initialization of
therapy (67% vs. 30%; p = 0.055). Moreover, cul-
tures of ascitic fluid obtained 3 hours after antimi-
crobial therapy were sterile. As for Gram staining,
the result was less influenced by the timing of
antimicrobial therapy. Therefore, it is preferable
to perform paracentesis before or immediately
after initiation of antimicrobial therapy, and mi-
crobiological cultures and Gram staining are of
value in establishing the diagnosis of SBP.
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The reported inhospital mortality rates of
SBP, mostly caused by Enterobacteriaceae, are 12–
42.2%.6,8,29–32 Likewise, the mortality rate of 
SBP caused by E. coli, the most common etio-
logical agent, is 20–44.4%.33 In contrast, in the
present study, Aeromonas SBP led to a higher
mortality rate (56%), similar to the 50% reported
by Huang et al.15 The poor prognosis of Aeromonas
infections was in accordance with the findings of
our earlier work. In a comparative experiment, 
a higher pathogenicity of A. hydrophila was in-
dicated by higher degrees of cytokine produc-
tion, and more rapid and intense inflammatory
reactions in affected muscles in a mouse model,
compared with that of E. coli or K. pneumoniae
isolates.34
Cefotaxime, a third-generation cephalosporin
with excellent penetration into ascites and with-
out nephrotoxicity, is the best-studied drug for
SBP.35 However, there is in vivo evidence of emer-
gence of antimicrobial resistance during cefo-
taxime therapy in cases of cefotaxime-susceptible
Aeromonas infections.13,36 Cefotaxime and mino-
cycline have been demonstrated to act synergis-
tically against A. hydrophila in a murine model,37
and ciprofloxacin is at least as effective as 
cefotaxime–minocycline combination for murine
A. hydrophila infections.38 As a result, antimicro-
bial therapy with a fluoroquinolone or combina-
tion of a third-generation cephalosporin and a
tetracycline analog are plausible alternatives for
systemic Aeromonas infections, but further study
is warranted.
In summary, clinicians should be highly alert
when cirrhosis patients with ascites present with
fever, abdominal pain, altered consciousness or
shock, which may be initial manifestations of
SBP. Prompt paracentesis should be performed
for early detection of SBP, and antimicrobial
therapy should be given before or immediately
after the sampling of blood and ascitic fluid.
Aeromonas SBP, although rare, is a fatal infectious
disease in patients with advanced liver cirrhosis.
In endemic areas, empirical antimicrobial therapy
should cover aeromonads for critically ill patients
with SBP.
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